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ABSTRACT 
Introduction: Acute Graft vs Host Disease (aGVHD) is a life-threatening, T-cell mediated immune 
reaction that may occur in allogeneic hematopoietic stem cell transplant (HSCT) patients. 
Tacrolimus is the cornerstone of aGVHD prophylaxis regimens for allogeneic HSCT patients, 
however it is a narrow therapeutic index drug. Tacrolimus is primarily metabolized through the 
CYP3A4 and CYP3A5 enzymes in the liver, and its concentrations could be impacted by two 
polymorphisms in CYP3A4 (CYP3A4*22, CYP3A4*1b) which may in turn impact onset and 
severity of aGVHD in allogeneic HSCT patients. Currently, the effect of these SNPs on tacrolimus 
trough concentrations and incidence and severity of aGVHD in allogeneic HSCT patients is 
unknown. The primary objective of this pharmacogenetics research study was to determine 
whether genetic variations in CYP3A4 influence steady-state tacrolimus concentrations, and are 
associated with risk of developing aGVHD in allogeneic HSCT patients. 
 
Methods: This is an observational, retrospective study where we analyzed 274 BMT patients who 
received their first allogeneic HSCT at the UNC health systems and received oral tacrolimus for 
aGVHD prophylaxis from January 2011 to May 2016 were identified through the UNC BMT 
database and 253 were retrospectively analyzed for incidence and severity of aGVHD. 
Genotyping for CYP3A4*22 and CYP3A4*1b was performed using TaqMan assays and RT-PCR 
on DNA collected for HLA-matching prior to transplant. Multivariate analyses will be performed  
 
Results: There was an approximate 60:40 ratio of males to females, and a 12% Black population 
represented in this study. Patients with two copies of the CYP3A4*1b variant allele (the CC 
homozygous genotype) had lower mean tacrolimus trough concentrations (4.06+2.06) than 
patients with the TT homozygous genotype (6.82+0.64, P=0.009). Patients with the CT genotype 
had lower tacrolimus trough concentrations than those with the TT genotype (3.9+0.95 vs 
6.82+0.95, P=0.14). For CYP3A4*22, patients with the AA or AG genotypes experienced higher 
tacrolimus trough concentrations (8.43+2.54) than patients with the GG genotype (6.3+0.59, 
P=0.14). Of the 253 patients analyzed, 116 patients experienced some manifestations of aGVHD 
and the most commonly targeted organ amongst them was the skin (68.9%). The second most 
targeted organ was the gastrointestinal tract (30.3%) and hepatic aGVHD was observed least 
frequently (0.8%).  
 
Conclusions: Patients with the CC or CT genotype for CYP3A4*1b experienced significantly 
lower tacrolimus trough concentrations than patients with the TT genotype. Patients with the AA 
or AG CYP3A4*22 genotypes experienced lower tacrolimus trough concentrations than patients 
with GG genotype, however this was not significant. There were no significant associations 
observed between CYP3A4*1b or CYP3A4*22 and incidence and severity of aGVHD. This is a 
preliminary study intended to generate data that can be applied to future population 
pharmacokinetic studies to tacrolimus dosing strategies based on genotype. Although there were 
no significant associations noted with aGVHD, this may be attributable to many clinical factors 
that could not be accounted for due to the retrospective design and these data need to be further 
analyzed using multivariate analyses to account for as many of these factors as possible. 
 
 
  
INTRODUCTION  
 Acute Graft versus Host Disease (aGVHD) is a potentially life-threatening complication that 
impacts approximately 40% of patients who have undergone allogeneic hematopoietic stem cell 
transplants (HSCT).1 In allogeneic HSCT, patients receive stem cells from an HLA-matched donor 
who may be related or unrelated to the patient. However, when donor-transplanted immune cells 
identify cells from the recipient as foreign, a T cell-mediated immune reaction takes place, which 
leads to the occurrence of GVHD.2,3Acute GVHD typically occurs within the first 100 days after 
transplant, and impacts the skin, liver and GI tract. 4 It can present as a maculopapular rash, 
elevated total bilirubin and/or diarrhea. Severity of aGVHD is classified as Grade I-IV using the 
Glucksberg Grading System, with Grade IV being the most severe form of the disease, and 
predictive of poorer outcomes. 5,6 Approximately 10% of patient deaths within the first 100 days 
are attributable to GVHD.7 aGVHD can be prevented in allogeneic HSCT patients by providing 
patients with optimal immunosuppressive therapy prior to HSCT. 
 Tacrolimus is a calcineurin inhibitor that is a cornerstone immunosuppressive therapy for the 
prevention of aGVHD in allogeneic HSCT patients.3 Tacrolimus binds to FK-binding protein-12 
(FKBP-12) and prevents the activation of the nuclear factor of activated T-cell (NFAT) family of 
transcription factors, consequently reducing the transcription of pro-inflammatory factors like 
interleukin-2 and the subsequent activation of effector T-cells (Figure 1).3 For appropriate 
immunosuppression, it is important to maintain tacrolimus trough concentrations within a 
therapeutic range of 5-10 ng/mL.8–10 This can present a challenge to clinicians because tacrolimus 
is a narrow therapeutic index drug, and its concentration could be influenced by many 
clinical/demographic factors (e.g., age, race, hepatic function, concomitant medications, and 
possibly germline genetics). Due to these factors, tacrolimus has large inter-patient 
pharmacokinetic variability and requires stringent monitoring for therapeutic and toxic 
concentrations. Traditionally, this is achieved through therapeutic drug monitoring, but this is a 
reactive approach, and achieving target trough concentrations can often take days to weeks.9,10 
Inadequate immunosuppression can lead to aGVHD, which could ultimately lead to death in 
severe cases.10 Conversely, supratherapeutic tacrolimus concentrations can also lead to severe 
adverse effects (e.g., nephrotoxicity, neurotoxicity and electrolyte imbalances).11  
 Tacrolimus is metabolized primarily by the cytochrome P450 enzymes in the liver, specifically 
CYP3A4 and CYP3A5. Although CYP3A5 is a major metabolizing enzyme for tacrolimus, a 
significant portion of its metabolism is mediated by CYP3A4.12–15 Therefore, CYP3A4 single 
nucleotide polymorphisms (SNPs) and their subsequent effect on tacrolimus concentrations, may 
play an important role too, especially if the patient has a CYP3A5 poor metabolizer genotype (i.e., 
CYP3A5*1/*1).  There are two SNPs in CYP3A4 that may impact tacrolimus concentrations in 
allogeneic HSCT patients: (1) rs35599367 occurs in an intronic region of CYP3A4, leads to a C>T 
base change, and is referred to as CYP3A4*22, and (2) rs2740574 occurs in the promoter region 
of CYP3A4, leads to a A>G base change and is referred to as CYP3A4*1b. Evidence from 
previous studies indicates that rs35599367 (CYP3A4*22) could be the most clinically relevant 
variant of CYP3A4.16  
 Currently, there is a need to optimize tacrolimus dosing to better achieve sufficient 
immunosuppressive effects of tacrolimus, and to potentially mitigate the incidence and severity of 
aGVHD or tacrolimus induced-toxicities. There are many factors that go into the clinical decision 
making process for dosing tacrolimus in allogeneic HSCT patients for aGVHD prophylaxis, and 
genotype information is one facet that could contribute to optimized tacrolimus dosing. The 
primary objective of this pharmacogenetics research study was to determine whether genetic 
variations in CYP3A4 influence steady-state tacrolimus concentrations, and are associated with 
risk of developing aGVHD in allogeneic HSCT patients.  
 
  
METHODS 
Study Design  
 This was a single-center, retrospective observational cohort study of allogeneic HSCT 
patients that evaluated the associations between two CYP3A4 variants (CYP3A4*22 and 
CYP3A4*1b) and two clinical phenotypes. The primary objective of this pharmacogenetics study 
was to evaluate associations between the two SNPs and steady state tacrolimus trough 
concentrations. The secondary objectives were to evaluate associations between the two SNPs 
and severity and time to onset of aGVHD. The primary endpoint of the study was initial steady 
state tacrolimus trough concentrations, while the secondary endpoints of the study were 
incidence, severity and time to onset of aGVHD. 
 
Study Population Identification 
 A total of 295 patients who underwent an allogeneic HSCT between January 2011 and May 
2016 at UNC Medical Center were identified from the UNC Bone Marrow Transplant Program 
database. To qualify for this study, patients were required to be 18 years or older, received their 
first (or only) allogeneic HSCT at UNC Medical Center, received long-term follow up care at UNC, 
and received oral tacrolimus for aGVHD prophylaxis starting on Day -3 (3 days before transplant). 
Eighteen patients were excluded because they were receiving their second allogeneic HSCT, 23 
were excluded because they did not provide written consent, and one was excluded due to 
insufficient DNA for genotyping (Figure 2).  
 
Clinical Data Extraction 
Clinical and demographic data for these patients was collected from the current UNC Health 
System electronic medical record (EPIC) and the legacy electronic medical record used prior to 
March 2014 (WebCis), as well as the UNC Bone Marrow Transplant Program database. 
Demographic data included: age at the time of transplant, sex, and self-reported race. Clinical 
data that was collected included: height, weight at the time of transplant, baseline Liver Function 
Tests (LFTs), baseline serum creatinine, diagnosis for which transplant was indicated, HLA 
match/mismatch, transplant type (allogeneic related or unrelated), source of transplanted cells 
(peripheral blood or bone marrow), conditioning regimen intensity (reduced intensity versus 
myeloablative), Karnofsky score (0-100), and date of transplant. Tacrolimus data that was 
collected included: date tacrolimus was initiated, initial dose, trough concentrations at goal, date 
first target trough concentration was achieved (5-10 ng/mL), and dose when at target trough 
concentration. Tacrolimus has a half-life of 12 hours, and it takes five half-lives to achieve a steady 
state serum concentration. Since tacrolimus was initiated on Day -3, Day 0 was deemed an 
appropriate time point for steady state tacrolimus trough measurements.17   
The incidence, severity of aGVHD (Table 1) and time to aGVHD onset were also collected for 
each patient. Grade I aGVHD is characterized by a rash over <25% of the body, bilirubin 2-3 
mg/dL and/or diarrhea of 500-1000 ml/day. Grade II aGVHD is characterized by a rash over 25-
50% of the body surface, an elevated bilirubin of 3-5mg/dL and diarrhea 1000-1500 mL/day. 
Grade III aGVHD is characterized by a rash covering >50% body surface, a bilirubin 6-15mg/dL 
and diarrhea >1500ml/day. Finally, the most severe form, Grade IV aGVHD, is characterized by 
bullae formation, ulcerative dermatitis, bilirubin>15mg/dL and severe abdominal pain with or 
without ileus.5,8  
For all aGVHD data, provider notes located in either EPIC or WebCis were accessed to obtain 
information regarding dates of onset, organs affected, and the severity of the reaction. When the 
clinical Grade for dermatologic aGVHD was not explicitly provided in the note, the total area of 
rash described in the note assisted with Grading. For hepatic aGVHD, changes in the total bilirubin 
from the date of diagnosis assisted with Grading. And for gastrointestinal aGVHD, a combination 
of physician-assigned initial Grade, the type of aGVHD treatment the patient received and 
biopsies were all factored to assist with Grading. The date, organ and severity of the first reaction 
were recorded, followed by information regarding subsequent progressive reactions.  
Of all the data points collected, initial steady state tacrolimus trough concentrations were used 
as the primary endpoint and evaluated for association with the two CYP3A4 variants. Incidence 
and severity of aGVHD, and time to onset of first aGVHD episode were assessed as secondary 
endpoints. Subgroup analyses were conducted based on organ affected by aGVHD (dermal, 
gastrointestinal or hepatic), number of patients with Grade II aGVHD or higher, and number of 
patients with Grade III aGVHD or higher. Other clinical and demographic variables that were 
assessed as covariates include race, age, sex, baseline liver function tests, baseline serum 
creatinine, conditioning regimen, diagnosis, matched related donor vs matched unrelated donor, 
HLA match, and concomitant medications,  
 
Measurement of Tacrolimus Blood Concentrations 
All tacrolimus concentrations from blood were quantified at the UNC McLendon laboratories. 
Whole blood samples were quantified using liquid chromatography (LC) tandem mass 
spectrometry (MS/MS). Whole blood samples were treated with a protein precipitant reagent 
containing internal standard. The samples were centrifuged and chromatographed using a Waters 
Alliance 2795 Separations Module and Waters Xbridge C18 2.5 uM, 4.6x50 mm column. MS/MS 
detection was performed in multiple reaction monitoring mode using ion transitions. The reference 
range for the analytical performance was 5-10 ng/mL, and the maximum dilution factor for sample 
measurement was x10. 
 
Genotyping Study Population 
DNA was obtained from UNC McLendon Labs (n=253), or directly from patient via buccal 
swab (n=1) (Genotek Inc, Murrieta, CA). For DNA obtained from McLendon Labs, patients had 
already provided samples for HLA-matching prior to their allogeneic HSCT. DNA obtained from 
the buccal swab sample was extracted using the Genotek prepIT L2P kit. DNA samples were 
quantified by measuring absorbance at 260 nm using a spectrophotometer (NanoDrop, 
Wilmington DE), and using the Quantifluor ONE dsDNA system (Promega, Madison, WI) in the 
UNC Center for Pharmacogenomics and Individualized Therapy at the UNC Genetic Medicine 
Building. Then, DNA concentrations were diluted to 50 ng/µL.  
Genotyping for rs35599367 and rs2740574 was performed using TaqMan assays (Applied 
Biosystems, Foster City, CA) and RT-PCR (QuantStudio 6, Applied Biosystems, Foster City, CA). 
A total of 120ng of patient DNA was loaded onto 384-well plates with the TaqMan probes and the 
TaqMan Genotyping Mastermix (Applied Biosystems, Foster City, CA) that contains VIC and FAM 
fluorescent reporter dyes to distinguish the reference base pair to the alternate base pair. Water 
and TaqMan Mastermix were used as negative controls. All patient samples were run in duplicate. 
For samples with ambiguous results (n=9), DNA will be amplified using PCR in the Crona 
Laboratory, and will be sent for Sanger sequencing to clarify the genotype. To avoid other sources 
of bias, reagents (e.g., Taq polymerase, TaqMan Mastermix and TaqMan probes) were acquired 
from the same manufacturer and had the same lot numbers. All the experiments were conducted 
by the same technician and on the same instrument to limit bias, and every plate contained control 
samples.  
 
Statistical Analyses  
Descriptive statistics of the clinical and demographic data was reported as medians, ranges 
and percentages. A level of 0.05 was selected for significance (P <0.05), and all analyses were 
two-sided. For all inferential statistics, parametric testing was used if data met three criteria: 
normal distribution, independent observations, and variance that is not significantly different 
between groups. Otherwise, equivalent non-parametric tests were used.  
 
Hardy-Weinberg Equilibrium (HWE) testing was first performed on the genotype data as an 
assay control, and to compare observed versus expected minor allele frequencies. Each of the 
two SNPs was considered to be within HWE if P>0.01. Univariate analyses of CYP3A4*22 and 
CYP3A4*1b versus mean trough concentrations was assessed individually using linear 
regression (i.e., the ANOVA test if SNPs are assessed in an additive genetic model, and t-test 
when assessed in a dominant/recessive model) since the data was found to be normally 
distributed. Then Dunnet’s correction was performed to evaluate pairwise comparisons of the 
three groups. Chi-square (or Fisher’s Exact Test when appropriate) were used to evaluate 
differences in incidence and severity of composite (all organs) aGVHD among CYP3A4*1b and 
CYP3A4*22 genotypes.  
Because some patients experienced aGVHD in more than one organ and some patients 
experienced no aGVHD, each event was treated as an individual observation, and not as an 
individual patient. Therefore, each data point was analyzed as either the presence or absence of 
aGVHD. If the condition was considered present, it was further characterized for severity of 
disease. Univariate models of CYP3A4*22 and CYP3A4*1b and time to develop aGVHD were 
assessed individually using log-rank test, which will also generate Kaplan Meier curves. 
Multivariate time to event analyses were then performed using a Cox Proportional Hazards 
Regression model to generate hazard ratios (HR) with 95% confidence intervals and p-values. 
An additive model of inheritance was assumed for CYP3A4*1b. We utilized a dominant model for 
CYP3A4*22, that combined the AA and AG genotypes because we observed only one AA 
genotype. All the statistical analyses performed in this study were conducted using SAS v9.4 
(Cary, NC), and all figures were created using GraphPad Prism v6 (GraphPad, La Jolla, CA). 
RESULTS 
Patient Demographic and Baseline Characteristics 
A total of 253 patients were consented and enrolled in the study. Of the 253 enrolled study 
patients, 245 were included in these analyses: 9 patients were excluded for inconclusive genotype 
calls, while 3 patients were excluded due to inconclusive aGVHD information. The median age at 
time of allogeneic HSCT was 52 (range 19-76), 145 men were enrolled versus 107 women (an 
approximately 60:40 ratio). The reported racial distribution included 211 White patients (84%), 30 
Black patients (12%) and 11 were classified as “other” (4%, which included Asian, Hispanic, 
Native American and Pacific Islander). Acute myeloid leukemia (AML) was the most common 
diagnosis (40%) that led to an allogeneic HSCT, and myelodysplastic syndrome (MDS) and acute 
lymphoblastic leukemia (ALL) were the second most common diagnosis (~15%). A majority of the 
patients received their transplant from an unrelated donor (n=165, 65%) versus a matched related 
donor (n=87, 35%). A total of 131 patients received myeloablative conditioning regimen (52%), 
while 121 patients received a reduced intensity conditioning regimen (48%). Table 2 includes a 
complete synopsis of all relevant baseline clinical and demographic characteristics for the study 
cohort. 
Patient CYP3A4*1b and CYP3A4*22 Genotyping 
In this study population, genotype calls were obtained for 245 patients for CYP3A4*1b, and 
for 245 patients for CYP3A4*22. For CYP3A4*1b, 201 (82%) patients had a TT genotype, 30 
(12%) patients had a CT genotype, and 14 (6%) patients had a CC genotype. For CYP3A4*22, 
235 (95.9%) patients had a GG genotype, 9 (3.7%) had an AG genotype, and only one (0.4%) 
patient had an AA genotype. Because the expected MAFs for CYP3A4*22 ranges from 0.001-0.5 
across the races represented in this study, Hardy Weinberg Equilibrium (HWE) analysis was 
conducted for the entire cohort and the SNP was found to be in HWE (P=0.11). In contrast, for 
CYP3A4*1b the T allele is the minor allele for Blacks and the MAF is 0.24, whereas the C allele 
is the minor allele for Whites and the MAF is 0.03. Therefore, when conducting the HWE analysis 
for these patients, they were first stratified by race to ensure appropriate use of the HWE were 
performed correctly. Once stratified by race, CYP3A4*1b was found to be in HWE (P=0.36 for 
Black patients, and P=0.53 for non-Black patients). Table 3 includes a complete synopsis of all 
relevant genotyping data for the study cohort. 
 
CYP3A4 Genotype Associations with Tacrolimus Trough Concentrations 
For CYP3A4*1b, patients with two copies of the variant allele (the CC homozygous genotype) 
had significantly lower mean tacrolimus trough concentrations than those with the TT 
homozygous genotype (4.06+2.06 ng/ml versus 6.82+0.64 ng/ml; P=0.009). Patients with the CT 
heterozygous genotype also had significantly lower mean tacrolimus trough concentrations as 
compared to patients with the TT genotype (3.90+0.96 versus 6.82+0.64 ng/ml); P=0.0003), but 
no difference in steady state mean tacrolimus trough concentrations were observed between 
patients with CC and CT genotypes (P=0.99) (Figure 3). For CYP3A4*22, there was a trend for 
patients with two copies of the variant allele (the GG homozygous genotype) to have lower 
tacrolimus trough concentrations that patients with the AA or AG genotype (6.30+0.59 ng/ml 
versus 8.43+2.54 ng/ml) however this was not significant (P=0.14) (Figure 3). 
 
CYP3A4 Genotype Associations with aGVHD   
Approximately 50% of patients experienced some form of aGVHD and the most commonly 
targeted organ amongst them was the skin (68.1%). The second most targeted organ was the 
gastrointestinal tract (31.0%). Hepatic aGVHD was observed least frequently in terms of aGVHD 
first incidence; however, select patients did develop hepatic aGVHD (0.9%) after their other 
organs were affected (Table 4).  
There were 7 incidences of Grade II or higher aGVHD, regardless of organ affected, among 
patients with the CC allele for their CYP3A4*1b genotype, 13 incidences in patients with the CT 
allele and 94 incidences in patients with the TT allele. When assessing for Grade III or higher 
aGVHD, there were 4 incidences in the CC allele group, 6 in the CT allele group and 34 in the TT 
allele group. However, significant differences in the incidence of Grade II+ and Grade III+ aGVHD 
were not observed among the CYP3A4*1b genotypes(P=0.94 and P=0.59, respectively; Table 5).  
When looking at patients with the CYP3A4*22 AA or AG allele, there were 3 total incidences 
of Grade II or higher aGVHD, and 100 incidences in the GG allele group. Of these incidences, 
two were grade III or higher in the AA or AG allele, and 41 in the GG allele group, When comparing 
the incidence of Grade II or higher and Grade III or higher aGVHD to CYP3A4*22 alleles, no 
significant differences were observed (P=0.44 and P=0.67, respectively; Table 5). 
Time to event analyses for all-grade aGVHD, Grade II+ aGVHD, and Grade III+ aGVHD by 
CYP3A4*1b and CYP3A4*22 genotype were performed. An additive model was used for the time 
to first incidence of aGVHD with TT as the referent group for the CYP3A4*1b genotypes. For the 
CYP3A4*22 genotypes and time to event analyses, a dominant model was used with GG as the 
referent group. Significant differences were not observed between CYP3A4*1b and time to all-
grade aGVHD (hazard ratio [HR 0.54], 95% confidence intervals [CI] 0.31-1.22; P=0.38), time to 
Grade II+ aGVHD (HR 0.53, 95% CI 0.26-1.46; P=0.40), time to Grade III+ aGVHD (HR 0.98, 
95% CI 0.24-4.08; P=0.94) (Figure 5). Similarly, significant differences were also not observed 
between CYP3A4*22 and time to all-grade aGVHD (HR 0.71, 95% CI 0.28-1.97; P=0.55), time to 
Grade II+ aGVHD (HR 0.71, 95% CI 0.23-2.45; P=0.63), and time to Grade III+ aGVHD (HR 2.04, 
95% CI 0.38-19.9; P=0.32) (Figure 6). 
 
DISCUSSION 
The primary objective of this pharmacogenetics research study was to evaluate if two CYP3A4 
SNPs (CYP3A4*1b and CYP3A4*22) associate with tacrolimus trough concentrations and 
secondary objectives included evaluating associations between the two SNPs and aGVHD 
incidence and severity. We conducted this study because there is an unmet clinical need to 
optimize tacrolimus dosing to better achieve proper immunosuppressive effects of tacrolimus, and 
to potentially mitigate the incidence and severity of aGVHD or tacrolimus induced-toxicities.  
Previous studies have associated germline SNPs in CYP3A4 and CYP3A5 with tacrolimus 
trough concentrations in the solid organ transplant setting, but these data from solid organ 
transplants cannot be directly extrapolated to HSCT patients because HSCT patients also 
develop chemotherapy-related complications like mucositis, renal dysfunction, and veno-
occlusive disease that may alter the bioavailability and clearance of tacrolimus.18 CYP3A4*22 has 
been extensively studied in solid organ transplant patients; however, its clinical significance in 
allogeneic HSCT patients has not yet been established.16,19,20 CYP3A4*22 appears to cause 
alternative RNA splicing, resulting in reduced production of full length CYP3A4 mRNA, and 
ultimately increased formation of a nonfunctional protein. An association between this SNP and 
supratherapeutic concentrations of tacrolimus has been observed in kidney transplant patients 
experienced.21 CYP3A4*1b has also been associated with decreased CYP3A4 activity which may 
also lead to higher tacrolimus steady-state concentrations.19  
In the current study of HSCT patients, there was a significant association observed between 
CYP3A4*1b and tacrolimus trough concentrations where patients with the CC or the CT genotype 
had significantly lower steady state tacrolimus trough concentrations on Day 0 as compared to 
patients with the TT genotype. This is consistent with the hypothesis that patients with the variant 
allele (T>C) would have lower tacrolimus trough concentrations.22 This suggests that patients with 
at least on C allele at rs2740574 may require higher initial doses of tacrolimus to achieve goal 
trough concentrations (5-10ng/ml). However, there was no significant association noted between 
CYP3A4*22 and tacrolimus trough concentrations. This could be attributed to the fact that only 
one AA genotype was observed and to see significance, we may need a population with a higher 
observed frequency for the alternate genotype.  
There were no significant associations observed between CYP3A4*1b or CYP3A4*22 and the 
incidence of all-grade aGVHD or more severe aGVHD (Grade II+ or Grade III+ aGVHD), or the 
time to aGVHD. Expected trends were observed when looking at CYP3A4*22 genotypes and 
steady state tacrolimus concentrations. Patients with the GG genotype had lower steady state 
trough concentrations and higher incidence of Grade II or higher aGVHD, whereas patients with 
the AA or AG genotype had lower incidence of aGVHD. However, the reverse was observed when 
observing CYP3A4*1b, where patients with the TT allele had slightly higher tacrolimus steady 
state concentrations but higher incidence of aGVHD.  
These observations about tacrolimus steady-state trough concentrations and aGVHD may 
have not reached our a priori determined threshold for significance due to the small population 
size, combined with a low minor allele frequency (particularly for CYP3A4*22). Other reasons for 
this could be the duration of time after transplant that was evaluated. Traditionally, aGVHD has 
been evaluated with the most scrutiny within the first 100 days of allogeneic HSCT. Therefore, 
analyses should be conducted using 100 days as a cut point (and possibly 60 days as well 
because of the high incidence of dermatologic aGVHD occurring within 60 days). Finally, most 
patients present with the mild form of the disease (Grade I) and therefore they may receive 
stringent monitoring and early interventions for the treatment of this first incidence that we do not 
observe the natural progression of the reaction as it relates to genotype. For validation of this 
result, both prospective and multi-institutional studies may be more benefit to compare the 
practice standards, and how aGVHD is diagnosed, managed and recorded in the EMR.  
One of the major strengths of this study is that it is a candidate gene/candidate SNP study, 
which may allow for quicker implementation into the clinic. The SNPs selected for this study 
(CYP3A4*22 and CYP3A4*1b) were identified through supportive literature that showed 
importance in tacrolimus pharmacokinetics in solid organ transplant recipients.20,21,23,24 The 
selection of specific SNPs, which may associate with aGVHD, could be more clinically relevant 
than genome-wide association study (GWAS), which analyzes the entire genome for genetic loci 
that may associate with a given phenotype. While GWAS could be potentially informative about 
the underlying biology of aGVHD, it may not yield results that are directly applicable to 
implementing genotype-guided precision dosing of tacrolimus.  
Another strength of this study lies in the demographics of the participants enrolled on the 
study. Unlike what was observed in a previous study from the City of Hope Hospital in California 
where Black patients were under-represented (<4%), approximately 12% of our patient population 
was Black.25 The MAF of CYP3A4*1b (T allele) is 0.24 in Black population, but the T allele is 
actually the major allele in the White population (MAF 0.97). Thus, since the C allele is associated 
with lower tacrolimus trough concentrations, Black patients may benefit most from genotyping as 
they are at higher risk for subtherapeutic initial tacrolimus trough concentrations. The higher 
percentage of Black population in this study gave us a higher probability of seeing the CC 
genotype in this population. Also, there was an almost 50:50 ratio of male to females, so this gives 
a better representation of the population allowing for better applicability into larger studies.  
One major limitation of this study is its retrospective design. Because the events had already 
occurred, there was no control over variables like dose adjustments, the extent of provider 
documentation and information collected, and administration of interacting medications. Also, 
since the clinical/demographic data was collected from two databases (UNC’s EMR EPIC, and 
the UNC BMT database), there were some inconsistencies in how clinical data was documented, 
especially since diagnosis, severity, and date of onset of aGVHD can be subjective.26 Harris et al. 
published a guidance document in January 2016 on how aGVHD should be assessed to include 
the extent of target organ involvement. However, measurements such as diarrhea output (based 
on volume) are not feasible to acquire in an outpatient setting, and the majority of our patients 
experienced gastrointestinal aGVHD once they were discharged from the hospital.  
Another limitation is that some patients followed up once weekly, whereas other patients 
followed up twice weekly. Therefore, some patients had more clinical aGVHD data than other 
patients, which could have potentially affected the recorded date of an aGVHD event (which could 
have affected our time to event analyses). Furthermore, we did not correct p-values in this study 
for multiple comparisons, and there is always a need in pharmacogenetics studies to correct for 
multiple comparisons to limit the likelihood of false positives due to type I error. However, we plan 
to conduct these analyses in the future. And, it is ideal for results from pharmacogenetics studies 
to be validated in independent, external cohorts of patients. We recognize this, and will be mindful 
of a plan for obtaining validation data from an external cohort as we plan our prospective studies.  
Data from this study is ultimately important for two reasons. This data can be used to develop 
a population pharmacokinetic model to test alternative tacrolimus dosing strategies and provides 
preliminary data for a prospective genotype-guided tacrolimus dosing trials in allogeneic HSCT 
patients. The CYP3A4*1b genotype testing is warranted in these studies as patients with the CC 
or CT genotype had lower tacrolimus trough concentrations and may require higher doses upon 
initiation of tacrolimus. CYP3A4*22 may also play a key role in the steady state tacrolimus trough 
concentration and should be evaluated for different tacrolimus dosing trials using a larger study 
population, particularly to evaluate the effect of the AA genotype on tacrolimus trough 
concentrations. Using the data from this study and future studies, we may be able to develop 
personalized tacrolimus dosing strategies in allogeneic HSCT patients, based on genotype and 
clinical factors to achieve goal tacrolimus trough concentrations by Day 0, and prevent the 
incidence and reduce the severity of aGVHD.   
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TABLES AND FIGURES 
Table 1. Acute Graft Versus Host Disease (aGVHD) Grading Severity. Severity for 
dermatologic, hepatic, and gastrointestinal aGVHD is based on the original Glucksberg criteria 
and is the criteria outlined in the UNC Bone Marrow Transplant protocol.5,8 
 
Grade Dermatologic Hepatic Gastrointestinal 
I Rash on <25% of skin 
Total bilirubin 2-3 
mg/dl 
Diarrhea > 500 ml/day or 
persistent nausea 
II Rash on 25-50% of skin 
Total bilirubin 3-6 
mg/dl 
Diarrhea >1000 ml/day 
III Rash on >50% of skin 
Total bilirubin 6-15 
mg/dl 
Diarrhea >1500 ml/day 
IV 
Generalized erythroderma 
with bullous formation 
Total bilirubin >15 
mg/dl 
Severe abdominal pain with or 
without ileus 
 
  
Table 2. Patient Baseline Characteristics. Baseline demographic and clinical data was 
collected through the UNC electronic medical records (EPIC and WebCis). Median values are 
represented with ranges in parentheses. Percentages are included for representation of the 
population. 
 
Variable Value 
Age (year) at transplantation, median (range) 51.6 (19-76) 
Sex 
Male 145 (57.6%) 
Female 107 (42.4%) 
Diagnosis 
Acute Myeloid Leukemia 102 (40.4%) 
Myelodysplastic Syndrome 40 (15.9%) 
Acute Lymphoblastic Leukemia 39 (15.4%) 
Non-Hodgkin's Lymphoma 22 (8.7%) 
Myeloproliferative Disorder 10 (4%) 
Chronic Myeloid Leukemia 10 (4%) 
Hodgkin's Lymphoma 9 (3.6%) 
Chronic Lymphoblastic Leukemia 7 (2.8%) 
Severe Anaplastic Anemia 5 (2%) 
Chronic Myelomonocytic Leukemia 5 (2%) 
Multiple Myeloma 3 (1.2%) 
Donor Type 
Matched Unrelated Donor 165 (65.4%) 
Matched Related Donor 87 (34.6%) 
Stem Cell Source 
Peripheral Blood Stem Cells 237 (94.0%) 
Bone Marrow 14 (5.6%) 
Cord 1 (0.4%) 
Conditioning Regimen 
Myeloablative Conditioning 131 (52.0%) 
Reduced Intensity Conditioning 121 (48.0%) 
Race 
White 211 (83.7%) 
Black 30 (11.9%) 
Other 11 (4.4%) 
Baseline Liver Function 
AST 33 (5-206) 
ALT 51 (12-209) 
Total Bilirubin 0.58 (0.1-2.5) 
Baseline Renal Function  
Serum Creatinine  0.79 (0.34-1.58) 
 
  
Table 3. Frequency of CYP3A4*22 and CYP3A4*1b Single Nucleotide Polymorphisms. 
Observed genotype frequencies for each SNP. Minor Allele Frequency (MAF) for CYP3A4*22 is 
2-5%, and MAF for CYP3A4*1b is 3-12% in Non-lack patients and 76% in Black patients. Hardy 
Weinberg Equilibrium (HWE) analyses were performed to ensure observed frequencies match 
the expected ones, and was a genotyping quality control measure. 
 
CYP3A4*22  
Alleles Patients (%) HWE (P-value) 
GG 235 (95.9%) 0.11 (All Patients) 
AG 9 (3.7%) 
 
AA 1 (0.4%) 
 
CYP3A4*1b (Non-Black population) 
Alleles  Patients (%) HWE (P-value) 
TT 166 (83.8%) 0.53 
CT 25 (12.6%)  
CC 7 (3.5%)  
CYP3A4*1b (Black population) 
Alleles  Patients (%) HWE (P-value) 
TT 16 (61.5%) 0.38 
CT 3 (11.5%)  
CC 7 (26.9%)  
 
 
  
Table 4. First Incidence of aGVHD by Severity. Of the patients who experienced an acute 
GVHD reaction, first incidence is represented by target organs overall and by the severity of the 
reaction 
 
Type of aGVHD Incidence (%) Median Days to First 
Incidence (range) 
All Grades n=116 
Dermatologic 79 (68.1%) 49 (10-175) 
Gastrointestinal 36 (31.0%) 49 (12-169) 
Hepatic 1 (0.9%) 56 (56) 
Grade I n=76 
Dermatologic 50 (65.8%) 47 (12-168) 
Gastrointestinal 26 (34.2%) 47 (12-169) 
Hepatic 0 (0%) - 
Grade II                                      n=32 
Dermatologic 23 (71.9%) 43 (10-175) 
Gastrointestinal 8 (25.0%) 59 (14-156) 
Hepatic 1 (3.1%) 56 (56) 
Grade III                                     n=8 
Dermatologic 6 (75%) 125 (28-155) 
Gastrointestinal 2 (25%) 47.5 (30-65) 
Hepatic 0 (0%) - 
 
  
Table 5. Incidence of aGVHD by Grade and CYP3A4 genotypes. Recorded incidences of 
Grade II or higher aGVHD and Grade III or higher aGVHD, as a composite of all organs, for 
CYP3A4*1b and CYP3A4*22 genotypes. Each number represents an individual observation, and 
not an individual patient, because some patients experienced aGVHD in more than one organ 
and some patients experienced no aGVHD. 
 
CYP3A4*1b 
Grade II+ aGVHD (n=242) 
Allele Yes No P-Value 
CC 7 77 0.94 
CT 13 167 
 
TT 94 1094 
 
Grade III+ aGVHD (n=242) 
Allele Yes No P-Value 
CC 4 38 0.59 
CT 6 84  
TT 34 560  
CYP3A4*22 
Grade II+ aGVHD (n=242)    
Allele Yes No P-Value 
AA or AG 3 24 0.44 
GG 100 1298  
Grade III+ aGVHD (n=242)    
Allele Yes No P-Value 
AA or AG 2 25 0.67 
GG 41 658  
 
  
Figure 1. Mechanism of Action of Tacrolimus. Tacrolimus inhibits calcineurin which prevents 
the activation of NFAT preventing the transcription of pro-inflammatory genes like IL-2. Figure 
adapted from Zeiser et al.3  
 
 
 
 
  
Figure 2. Study CONSORT Chart. This represents the screening, follow-up and analysis of 
eligible allogenic HSCT study patients. The total number of patients originally identified was 295, 
but a total of 253 were included in the final cohort  
 
  
Figure 3. Tacrolimus Trough Concentrations Versus CYP3A4*1b Genotype. An additive 
genetic model was used to compare initial steady state tacrolimus trough concentrations on the 
day of allogeneic HSCT (Day 0) to genotypes for CYP3A4*1b. Mean tacrolimus trough 
concentration are represented below with respective standard deviations for each of the 
genotypes. 
 
 
 
  
Figure 4. Tacrolimus Trough Concentrations Versus CYP3A4*22 Genotype. A dominant 
genetic model was used to compare initial steady state tacrolimus trough concentrations on the 
day of allogeneic HSCT (Day 0) to genotypes for CYP3A4*22. A dominant genetic model was 
chosen because only one AA genotype was observed. Mean tacrolimus trough concentration are 
represented below with respective standard deviations for each of the genotypes. 
 
 
  
Figure 5. Time to Event Analyses for aGVHD and CYP3A4*1b. Kaplan-Meier plots show the 
percentage of patients who experienced all-grade aGVHD (left panel), Grade II or higher aGVHD 
(middle panel), or Grade III or higher aGVHD (right panel) during the first 180 days post-allogeneic 
HSCT for each CYP3A4*1b genotype.  
 
  
 
  
P=0.38 P=0.40 P=0.94 
Figure 6. Time to Event Analyses for aGVHD and CYP3A4*22.  
Kaplan-Meier plots show the percentage of patients who experienced all-grade aGVHD (left 
panel), Grade II or higher aGVHD (middle panel), or Grade III or higher aGVHD (right panel) 
during the first 180 days post-allogeneic HSCT for each CYP3A4*22 genotype.  
 
 
 
 
 
P=0.55 P=0.63 P=0.32 
